Entrada Therapeutics (TRDA) Current Leases (2022 - 2026)

Entrada Therapeutics has reported Current Leases for 5 years, with the latest figure at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 34.24% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (down 34.24% YoY), and the FY2025 full-year result was $4.1 million, down 45.26% from the prior year.
• Current Leases for Q1 2026 stood at $4.3 million, up from $4.1 million in the prior quarter.
• The five-year high for Current Leases was $8.6 million in Q2 2024, with the low at $4.1 million in Q4 2025.
• Average Current Leases over 5 years is $7.0 million, with a median of $7.6 million recorded in 2024.
• Year-over-year, Current Leases climbed 16.87% in 2024 and tumbled 45.26% in 2025.
• Tracing TRDA's Current Leases over 5 years: stood at $8.4 million in 2022, then slipped by 5.91% to $7.9 million in 2023, then slipped by 4.43% to $7.6 million in 2024, then sank by 45.26% to $4.1 million in 2025, then advanced by 3.46% to $4.3 million in 2026.
• The last three Current Leases figures came in at $4.3 million (Q1 2026), $4.1 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.

Peer Comparison